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Randomized trials in patients with hospitalized heart failure (HHF)
continue to frustrate the cardiology community. Promising haemo-
dynamic, structural and biomarker findings from phase 2 studies
consistently fail to deliver substantive benefits in larger outcome
trials. What underlies these recurrent failures? Why are persis-
tently high readmission and post-discharge mortality rates not
being reduced? Challenging any pre-conceived ideas about the exis-
tence of a ‘typical’ acutely decompensated heart failure patient
is fundamental, as is the adoption of a carefully personalized
approach. These individuals come from a remarkably heteroge-
neous group. Surely precise phenotyping should translate to a more
successful therapeutic approach?
Lack of robust consideration
of the presenting phenotype
In our opinion, it is unrealistic to expect a change in outcomes until
a personalized approach is adopted (Figure 1). This includes cate-
gorizing the heart failure aetiology, presenting clinical phenotype
and precipitant of hospitalization. Detailed and precise investiga-
tion of the heart, broader cardiovascular system and co-morbidity
is required (Table 1). Once the reason for HHF is known, existing
treatments can be applied (primarily loop diuretics and nitrates)
and novel investigational drugs and techniques or devices can be
assessed. Applying one therapy in patients with different aetiolo-
gies and mechanisms has been surprisingly successful in the more
homogeneous ambulatory population with chronic heart failure
and reduced ejection fraction (HFrEF), but in HHF this broad-brush
approach has not been effective.
Patients who present primarily with dyspnoea at rest comprise
up to 42% of ‘real-world’ patients with HHF in registries1 but
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. over 90% in randomized controlled trials.2 Those who present
with peripheral oedema as their main complaint and who are
only breathless on exertion have worse outcomes than those with
pulmonary congestion and consequent breathlessness at rest.1 In
clinical trials, it is likely that the under-representation of patients
with predominant peripheral oedema dilutes treatment effects. We
would argue that there is a growing need to separate these groups
in the design of trials assessing mechanistically-targeted therapies.
Differentiation of those with a slower ‘sub-acute’ decline in their
condition from those with ‘acute’ breathlessness has only recently
received attention.1 Perhaps those who present with increasing
symptoms over weeks or months have fluid overload as their pri-
mary therapeutic target. The minority who present with a true
‘acute decompensation’ in the absence of a slow, often sub-clinical,
accumulation of fluid might have uncontrolled hypertension, unsta-
ble coronary disease or an acute arrhythmia as a precipitant, and
thus require quite different treatment approaches. It seems logical
that targeting the cause or causes of decompensation should yield
better long-term benefits than the undifferentiated treatment of
the resulting signs and symptoms.
HFrEF and heart failure and preserved ejection fraction (HFpEF)
represent different cardiac phenotypes that are likely to respond
to distinct therapeutic interventions. However, providers may be
criticized for failing to think ‘beyond the ejection fraction’. For
example, a patient with HFrEF as a result of a large prior myocar-
dial infarction and scar could respond differently to a therapy than
might a patient with HFrEF due to an acute toxic insult, myocardi-
tis, or poorly controlled systemic hypertension. Establishing the
incremental benefits of such phenotypically-targeted therapies
(in addition to renin–angiotensin–aldosterone system inhibitors
and beta-blockers in HFrEF) would require stricter trial inclusion
criteria.
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Dichotomies in the approach to hospitalized heart failure (HHF). HFrEF, heart failure with reduced ejection fraction.
Over-optimistic expectations
of the long-term benefits
of short-term infusions
Many clinical trials in HHF have investigated short-term infu-
sions of vasoactive therapies3 with attractive biological profiles.
These have been drugs that may well have produced short-term
effects on the heart, vasculature and kidneys. In retrospect, it
was perhaps overly optimistic to think that a short-term infu-
sion might result in a reduction in major clinical events such
as death or recurrent HHF. However, short-term therapies can
reduce inpatient mortality and morbidity, which is sustained in
the longer term in patients with acute myocardial infarction.4
It is, therefore, not impossible that short-term treatment can
have long-term benefit, but demonstration of the small effects of
beta-blockers4 and angiotensin-converting enzyme inhibitors5 in
acute myocardial infarction required the randomization of large
numbers of patients. Alternatively, continuation of oral therapy
after early intravenous infusion might be beneficial in HHF (with
beta-blockers in acute myocardial infarction another analogous
example).6
Possible cardiac targets
in hospitalized heart failure
Exciting times may lie ahead. Careful phenotyping (Table 1) could
lead to trials of new therapies in tightly defined groups. Studies ..
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.. of catheter ablation for atrial fibrillation could be launched in
both HHF secondary to HFrEF, HFpEF, or both. Trials of coro-
nary revascularization with percutaneous intervention or coro-
nary artery bypass grafting are overdue and could be performed
in HHF – again in HFrEF, HFpEF, or both. Impressive benefits
of transcatheter mitral valve intervention have been demon-
strated in very carefully selected patients with chronic HFrEF.7 It
remains to be established whether these benefits can be extended
to the HHF population, and the potential beneficial effects of
tricuspid and aortic valve interventions remain undefined in
this group.
Possible co-morbidity targets
in hospitalized heart failure
Many co-morbidities have long been recognized to be targets
for treatment in HHF including diabetes, lung disease, renal failure,
iron deficiency and anaemia, among others. Indeed, trials investi-
gating the potential benefit of sodium–glucose co-transporter 2
(SGLT2) inhibition in diabetic patients with HHF8 and of intra-
venous iron in HHF are ongoing.9 The role of lung infections in
precipitating HHF is well recognized.10 However, the protective
effects of influenza vaccination upon HHF are surprisingly poorly
defined. This is the focus of an ongoing trial including patients
with heart failure and comparing the effect of high vs. low-dose
influenza vaccination upon all-cause mortality and cardiopulmonary
hospitalization.11
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Personalized assessment of hospitalized heart failure
System Assessments
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cardiac
Left and right ventricular and atrial function
Rhythm
QRS duration
Coronary vasculature
• Epicardial and microvascular
Valvular assessment
Intra-cardiac pressures
Pericardial assessments
Vascular
Arterial blood pressure
Pulmonary pressures and haemodynamics
Venous pressures
• Cardiac preload, renal afterload
Peripheral vascular disease
• Aorto-iliac, mesenteric
Renovascular disease
Cerebrovascular disease
Co-morbidity
Renal function
Hepatic structure and function
Diabetes
Lung disease
Anaemia/iron deficiency
Obesity
Infection
Cancer
Psychological
Psychological (anxiety, depression)
Cognitive impairment
Frailty
Adherence to medication
Social Housing
Isolation
Access to healthcare services
Many of the co-morbidities found in patients with HHF have
not been perceived to fall within the purview of cardiology but
recognizing them may improve outcomes. Perhaps early diagnosis
of cognitive impairment or psychological conditions could provide
benefit. Establishing the social environment of a patient can reveal
obvious ways to influence readmission.12 Can the patient afford
the drugs they are prescribed? Do they have ready access to a
pharmacy? How deep is their social support network?
Research to target poor outcomes
after discharge from hospital
Outcomes remain poor after discharge from an admission
with heart failure.13 This high-risk period is an opportunity for ..
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.. more research to understand causes of rehospitalization and
death. Future treatments may potentially be targeted at these
events. What proportion of deaths and readmissions are due to
rhythm disturbance? We need to better understand what hospi-
talization represents – is it just a marker of a patient at higher
risk or does the deterioration leading to admission (or what
happens in hospital, or both) directly depress the life trajectory of
these patients? Does irreversible cardiac, renal or other organ or
tissue damage occur? Can this risk be modified? Perhaps earlier
implantation of a defibrillator or cardiac resynchronization therapy
device yields benefit in select cases? How many patients have
persistent fluid overload at discharge and might benefit from more
aggressive diuresis (perhaps from SGLT2 inhibitors rather than
bigger doses of loop diuretics)? Persistent unrecognized fluid over-
load could be identified by lung ultrasound.14 In patients with early
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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and frequent readmission, wireless pulmonary artery pressure
monitoring, or other techniques might be assessed as a prevention
strategy.
A key focus should be to improve equity of access to heart
failure management programmes, including follow-up by a heart
failure nursing team and allied health practitioners. By taking
this more comprehensive approach, the psychological, social and
economic issues that might negatively influence outcomes should
become clearer. Research to address many of these questions is
overdue and the bulk of currently available evidence is based on
subgroup analysis which is, therefore, hypothesis-generating and
not definitive.
Expanding the use of mechanical
circulatory support in hospitalized
heart failure beyond their present
niche
Durable ventricular assist devices (VADs) remain a niche therapy
for few and highly selected patients in a small number of centres
in the United States, Germany and some other countries. Notwith-
standing the considerable cost of these devices and substantial
resources required to care for patients post-implant, there is a
major opportunity to test durable VADs against conventional HHF
treatment in patients towards the sickest end of the spectrum.
The mainstay of therapy for these patients is inotropes – some
of which are known to increase rather than decrease mortality. A
trial of durable VADs vs. inotropes in countries where VADs are
not used or funded would potentially lead to convincing evidence
of the benefit of these devices as destination therapy (to date only
129 patients have been randomized to durable VADs or medical
therapy).15 Intra-aortic balloon pumps may also have a role in HHF
but no trial has yet been performed (a trial of cardiogenic shock
in acute myocardial infarction – a very different condition – was
neutral).16
Conclusion
Trials in HHF have resulted in failure. The ‘typical’ HHF patient
does not exist. A change of direction is necessary with a new
era of personalized assessment. Management of these complex
patients requires assessment that is not limited to the presenting
features but extended to the nuances of aetiology, precipitants
of decompensation and co-morbidity. Only by doing so will we
identify phenotypically similar groups of patients with HHF who
can enter trials to understand which pharmacological, monitoring
or device therapies might finally lead them to a brighter prognosis.
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